2. Disease Areas
  3. Blood or Cardio-cerebrovascular Disease
  4. Blood Disease
  5. Platelet Disease

Platelet Disease

Platelet diseases encompass disorders involving abnormal platelet count or function, leading to impaired blood clotting and increased bleeding risk. These include thrombocytopenia (low platelet count), thrombocytosis (high platelet count), and platelet dysfunction such as in von Willebrand disease. Causes range from autoimmune conditions like immune thrombocytopenia (ITP), blood cancers, medications, and liver disease to inherited disorders. Symptoms typically involve easy bruising, petechiae, prolonged bleeding, and heavy menstrual periods. Treatment varies by cause and severity, ranging from observation and medication to transfusions or bone marrow transplantation, with outcomes dependent on the underlying condition.

Platelet Disease (45):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113308
    Taurolithocholic acid 516-90-5 99.7%
    Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis (Ferroptosis), viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
    Taurolithocholic acid
  • HY-P990685
    Romiplostim 267639-76-9 ≥99.0%
    Romiplostim is an Fc-peptide fusion protein mimetic of TPO (thrombopoietin protein) and also a c-Mpl agonist. Romiplostim binds to c-Mpl, stimulates megakaryocyte-mediated thrombopoiesis, and activates the same downstream signaling pathways as endogenous TPO. Romiplostim is applicable to research related to hematopoietic acute radiation syndrome and chronic immune thrombocytopenia.
    Romiplostim
  • HY-P5354
    FRETS-VWF73
    FRETS-VWF73, a 73-amino-acid peptide, is a fluorogenic substrate for ADAMTS13 assay (Ex = 340 nm; Em = 450 nm). FRETS-VWF73 is a predictive tool for thrombotic thrombocytopenic purpura.
    FRETS-VWF73
  • HY-170506
    KB-208 1282128-68-0 98.00%
    KB-208 is a phagocytosis inhibitor. KB-208 inhibits phagocytosis of antibody-opsonized blood cells. KB-208 ameliorates thrombocytopenia in a mouse model of passive antibody-induced immune thrombocytopenia. KB-208 can be used for the research of immune thrombocytopenia.
    KB-208
  • HY-N0120
    (E/Z)-Polydatin 65914-17-2 98.13%
    (E/Z)-Polydatin ((E/Z)-Piceid) is a mixture of the E/Z configurations of Polydatin (HY-N0120A). Polydatin can be isolated from Polygonum cuspidatum, grapes, peanuts, red wine, hop pellets, cocoa-containing products and chocolate products. Polydatin exhibits multiple biological properties, such as anti-platelet aggregation, anti-low-density lipoprotein oxidation, cardioprotective activity, anti-inflammatory and immunomodulatory functions. Polydatin shows favorable cytotoxic effects against various tumor cell lines, including cervical cancer cells, liver cancer cells, and nasopharyngeal carcinoma cells.
    (E/Z)-Polydatin
  • HY-P991888
    INCA033989
    INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (KD = 1.75 nM for mutCALRdel52; KD = 6.78 nM for mutCALRins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .
    INCA033989
  • HY-W870794
    Pirprofen 31793-07-4 ≥99.0%
    Pirprofen (SU 21524) is an orally active non-steroidal anti-inflammatory agent. pirprofen is a reversible prostaglandin synthetase inhibitor. Pirprofen inhibits leucocyte chemotaxis. Pirprofen shows anti-inflammatory, analgesic, antipyretic, ulcerogenic activities. Pirprofen inhibits the secondary phase of platelet aggregation induced by Collagen and Arachidonic acid (HY-109590). Pirprofen induces hepatitis.
    Pirprofen
  • HY-182557
    KC-11404 148490-22-6
    KC-11404 is an orally active antihistamine and 5-lipoxygenase inhibitor, with an IC50 of 0.9 μM against guinea pig 5-lipoxygenase. KC-11404 inhibits histamine-induced contraction of isolated guinea pig ileum with an IC50 of 0.26 μM. KC-11404 inhibits PAF-induced rabbit platelet aggregation with an IC50 of 2.0 μM. It inhibits the histamine phase of antigen-induced bronchoconstriction and PAF-induced bronchoconstriction in guinea pigs. KC-11404 can be used for the research of asthma.
    KC-11404
  • HY-131150
    Ristomycin sulfate 11140-99-1 99.0%
    Ristomycin sulfate is an antibacterial antibiotic and platelet aggregation inducer. Ristomycin sulfate interacts with the D-alanyl-D-alanine terminus of bacterial cell wall precursors to regulate bacterial cell wall synthesis. Ristomycin sulfate induces platelet aggregation in vitro and inhibits the growth of Gram-positive bacteria. Ristomycin sulfate serves as an in vitro diagnostic compound for detecting von Willebrand factor activity. Ristomycin sulfate is applicable to research related to von Willebrand disease and Bernard-Soulier syndrome.
    Ristomycin sulfate
  • HY-N4183
    Licoflavone C 72357-31-4 99.83%
    Licoflavone C is a broad-spectrum antiviral inhibitor with estrogen-like properties. Licoflavone C binds to viral endonuclease (CEN) and inhibits the replication of various bunyaviruses including severe fever with thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus in a non-substrate competitive manner. The IC50 values of Licoflavone C against SFTSV CEN and SFTSV CEN are 35.5 μM and 135.8 μM, respectively, and its Kd value against SFTSV CEN is 9.53 μM. After viral entry into cells, Licoflavone C reduces viral loads in mouse tissues in a dose-dependent manner, and exhibits extremely low cytotoxicity and genotoxicity. Licoflavone C induces apoptosis by increasing caspase 3/7 activity, blocks the cell cycle, and alleviates chemotherapy-induced chromosomal damage. Licoflavone C is applicable to the research on severe fever with thrombocytopenia syndrome and related viral infection mechanisms.
    Licoflavone C
  • HY-138053
    Ristocetin A sulfate 90831-71-3
    Ristocetin A sulfate (Ristomycin III) is a glycopeptide antibiotic that binds to von Willebrand factor (VWF) and bacterial cell wall components. Ristocetin A sulfate interferes with the biosynthesis of bacterial peptidoglycan by inhibiting transpeptidation. As an inducer of platelet adhesion and aggregation, Ristocetin A sulfate drives conformational changes by binding to the A1 domain of VWF, thereby activating downstream signaling pathways and promoting cytoskeletal rearrangement. Ristocetin A sulfate not only enhances platelet adhesion and spreading on immobilized VWF, but also induces the formation of asymmetric dimers with anticooperativity between platelets and plasma VWF. Ristocetin A sulfate is widely used in studies related to thromboembolic diseases and bacterial infections.
    Ristocetin A sulfate
  • HY-P990060
    Denecimig 2488745-86-2
    Denecimig (Mim8) is a factor VIII-mimetic bispecific antibody with micromolar human binding affinity for Factor X and Factor IXa. Denecimig binds Factor X and Factor IXa, localizes both to the phospholipid surface, enhances the Factor IXa-mediated activation of Factor X to Factor Xa, and stimulates the proteolytic activity of Factor IXa via its monovalent anti-Factor IXa arm. Denecimig is applicable to research related to hemophilia A.
    Denecimig
  • HY-116442
    Azapropazone 13539-59-8 99.67%
    Azapropazone is an orally active nonsteroidal anti-inflammatory agent. Azapropazone inhibits Xanthine oxidase activity with an IC50 of 70-140 μg/mL. Azapropazone exerts significant cardiomyocyte protective effects on dogs with ischemia-reperfusion injury. Azapropazone reduces arthritis. Azapropazone inhibits Adrenaline-induced platelet aggregation. Azapropazone can be used for the research of myocardial ischemia and reperfusion injury, adjuvant arthritis, and gouty arthritis.
    Azapropazone
  • HY-126967A
    1-Palmitoyl-sn-glycerol 3-phosphate 7220-34-0 99.0%
    1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is a phospholipid and lipid membrane precursor. 1-Palmitoyl-sn-glycerol 3-phosphate integrates into POPC liposomes, causing significant changes in membrane curvature. 1-Palmitoyl-sn-glycerol 3-phosphate induces platelet aggregation, but its activity is 30-fold lower than that of 1-hexadecyl-sn-glyceryl-3-phosphate.
    1-Palmitoyl-sn-glycerol 3-phosphate
  • HY-N0320
    Salvianolic acid D 142998-47-8
    Salvianolic acid D is a depside. Salvianolic acid D can be isolated from Salvia miltiorrhiza (Danshen). Salvianolic acid D promotes the expression of Bcl-2, and inhibits the expressions of Bax, Cleaved caspase-3 and -9. Salvianolic acid D reduces the expression levels of TLR4, MyD88 and TRAF6 proteins both in vitro and in vivo, and significantly inhibits the nuclear translocation of NF-κB. Salvianolic acid D inhibits the cytoplasmic translocation of HMGB1. Salvianolic acid D suppresses inflammatory responses and alleviates cerebral ischemia-reperfusion injury. Salvianolic acid D serves as a potential antiplatelet active component.
    Salvianolic acid D
  • HY-118028
    Leyk 1950-36-3 99.99%
    Leyk is an orally active Cysteine derivative. Leyk stimulates bone marrow hematopoiesis. Leyk exerts a significant protective effect against cyclophosphamide-induced leukopenia. Leyk can be used in studies related to thrombocytopenia and leukopenia.
    Leyk
  • HY-P99952
    Ripertamab 2249927-04-4
    Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy.
    Ripertamab
  • HY-P991029
    Sutacimig 2933972-64-4 99.08%
    Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia.
    Sutacimig
  • HY-N3228
    Myrianthic acid 89786-84-5 98.0%
    Myrianthic acid is a pentacyclic triterpenoid compound. Myrianthic acid can exist in the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora. Myrianthic acid inhibits adrenaline-induced platelet aggregation, with a IC50 of 46.2 μM for this activity. Myrianthic acid can be used in studies related to thrombosis.
    Myrianthic acid
  • HY-W744923
    Bis[2-(4-hydroxyphenylthio)ethoxy]methane 93589-69-6 99.59%
    Bis[2-(4-hydroxyphenylthio) ethoxy]methane (DD-70) is a Bisphenol A (HY-18260) substitute and a COX-1 inhibitor. Bis[2-(4-hydroxyphenylthio) ethoxy]methane blocks platelet aggregation induced by Arachidonic acid (HY-109590) and U-46619 (HY-108566). Bis[2-(4-hydroxyphenylthio) ethoxy]methane alters hemostatic function. Bis[2-(4-hydroxyphenylthio) ethoxy]methane reduces embryonic survival rate, decreases embryonic mass and increases gallbladder mass in chicken embryos.
    Bis[2-(4-hydroxyphenylthio)ethoxy]methane